Metformin Vicious Cycle

Skeletal muscle is responsible for roughly 80% of the work your body does to clear glucose out of your bloodstream after a meal, and that one number explains more about type 2 diabetes than almost anything else in the literature.

When you eat, your blood sugar rises, insulin gets released, and your cells are supposed to respond by pulling that glucose in. Most of that response happens in muscle tissue. Not fat tissue, not the liver doing the bulk of the clearing, but muscle. So when muscle mass drops, or when muscle stops responding to insulin properly, you have lost the primary system your body relies on to keep blood sugar stable. That is not a contributing factor to insulin resistance. That is one of its core mechanisms.

This is the starting point for understanding what metformin actually does inside the body, and why the story is more complicated than it looks on the surface.

Metformin works by inhibiting something called Complex I, which is one of the first steps in the chain your mitochondria use to produce energy. When Complex I gets inhibited, the ratio of a molecule called AMP to ATP shifts, meaning the cell is detecting an energy deficit, and that activates an enzyme called AMPK, which stands for AMP-activated protein kinase and functions essentially as the cell's low-fuel sensor. When AMPK turns on, the cell starts pulling in glucose from the bloodstream to restore energy balance, and that is the mechanism behind why metformin lowers blood sugar. It genuinely works, and that part of the story is real.

But AMPK does more than one thing, and this is where the problem starts.

AMPK also suppresses something called mTOR, specifically a complex called mTORC1, which is the primary signaling pathway your body uses to build new muscle protein after training. It does this through at least two confirmed routes: one involves a protein called TSC2 that when activated by AMPK puts the brakes on mTOR signaling, and the other involves a separate protein called Raptor that AMPK phosphorylates directly to inhibit mTORC1 activity. Both pathways point in the same direction. When AMPK is chronically elevated, mTOR gets suppressed, and muscle protein synthesis goes down.

Think of it this way. mTOR is the gas pedal for muscle building. AMPK is the brake. Metformin holds down the brake.

This would be a theoretical concern worth noting and moving on from if the human data did not exist. But it does.

A randomized controlled trial called the MASTERS trial enrolled 94 adults over the age of 65 and put them through 14 weeks of progressive resistance training. Half took metformin, half took a placebo. The researchers actually expected metformin to enhance muscle growth because of its known anti-inflammatory effects, and inflammation is one of the factors that limits adaptation in older adults. So the prediction going in was that metformin would help.

The opposite happened. The placebo group gained significantly more muscle mass and more muscle density than the metformin group. The drug did not just fail to help. It blunted the adaptation.

A separate trial looked at what metformin does to mitochondrial adaptation from exercise specifically, and found that metformin blocked the improvements in mitochondrial function that aerobic exercise normally produces. This matters because mitochondrial health in muscle tissue is one of the mechanisms through which exercise improves insulin sensitivity in the first place. The exercise is supposed to restore the very thing the disease has degraded, and metformin appears to interfere with that process.

Now, the standard defense of metformin is that any blunting of muscle adaptation is a minor tradeoff against meaningful reductions in blood sugar, cardiovascular risk markers, and all-cause mortality in diabetic populations. That is a legitimate argument and the long-term outcome data for metformin in type 2 diabetics is real. The drug has been studied for decades and the evidence for it reducing serious complications is not nothing.

But that framing misses the structural problem, and this is what the video is actually pointing at.

Insulin resistance in people who lack adequate muscle mass is, at its foundation, a problem of tissue. You do not have enough of the primary glucose-clearing tissue, and what you have does not respond well to insulin. The long-term fix for that is rebuilding the tissue and restoring its sensitivity, and resistance training is the most direct tool for doing both of those things simultaneously. It increases muscle mass, and it improves the insulin sensitivity of the muscle you already have through mechanisms that are entirely separate from the pharmaceutical pathway.

The cycle that forms is this: low muscle mass drives insulin resistance, insulin resistance eventually gets a metformin prescription, metformin's AMPK activation suppresses mTOR, mTOR suppression blunts the muscle-building response to training, and so the person stays muscle-deficient, stays insulin resistant, and the root cause never actually gets addressed.

This does not mean metformin is being prescribed irresponsibly or that the doctors are wrong to use it. It means that if the goal is to get out of the situation rather than manage it indefinitely, the drug and the training are working against each other in a specific and mechanistically understood way, and that is worth knowing before you build a plan.

The practical takeaway is straightforward. If you are on metformin and you are doing resistance training with the goal of improving your insulin sensitivity over time, the question worth raising with your doctor is whether metformin is still serving you at that stage, or whether it was a bridge that made sense early on but is now limiting the adaptation that would make it unnecessary.

Muscle is not a side benefit of treating insulin resistance. It is the organ you are trying to fix.

---

References

1. DeFronzo RA et al. (1981). "The effect of insulin on the disposal of intravenous glucose." J Clin Invest. 68(6):1468-1474. Finding: Skeletal muscle responsible for approximately 80% of insulin-mediated glucose disposal. PMID: 7033285
2. DeFronzo RA (2009). "From the triumvirate to the ominous octet." Banting Lecture. Diabetes Care. 32(Suppl 2):S157-S163. Finding: Muscle insulin resistance is a core defect in type 2 diabetes. PMID: 19875544
3. Walton RG et al. (2019). "Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: The MASTERS trial." Aging Cell. 18(6):e13039. Finding: n=94, adults 65+, placebo group gained significantly more muscle. PMID: 31557380
4. Konopka AR et al. (2019). "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell. 18(1):e12880. Finding: Metformin blocked exercise-induced mitochondrial improvements. PMID: 30548390
5. Drewe J et al. (2026). "Metformin: Mechanism of action." Pharmacol Rev. Finding: Complex I inhibition activates AMPK. PMID: 41389439
6. Inoki K et al. (2003). Nat Cell Biol. Finding: AMPK phosphorylates TSC2, suppressing mTOR. PMID: 12847286
7. Gwinn DM et al. (2008). Mol Cell. Finding: AMPK phosphorylates Raptor to suppress mTORC1. PMID: 18439900
8. Bolster DR et al. (2002). J Biol Chem. Finding: AMPK activation reduces muscle protein synthesis through mTOR suppression. PMID: 12351658

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness